FK506 is an efficient immunosuppressive agent with an increasing number of clinical applications. It has been approved to prevent rejection in transplant patients and be efficacious in several autoimmune diseases. Its immunosuppressive activity results from binding to receptor proteins designated as immunophilins (i.e., FKBP12, FK506 binding protein). Recent studies have suggested that FK506 can promote neurite outgrowth as a 2nd activity. Furthermore, it has been shown that the neurotrophic property of FK506 is independent of its immunosuppressive action. Although the mechanism of its neurotrophic activity has not yet been well elucidated, FKBP12 is identified as a drug target, and much effort has been directed toward the design of FKBP12-binding molecules, which are neurotrophic but nonimmunosuppressive, for clinical use. In this present study, the authors constructed a stable cell line, which underwent apoptosis upon treatment by AP20187, a wholly synthesized, cell-permeable dimeric FK506 derivative, based on FKBP12-mBax dimerization. This AP20187-mediated apoptosis was rapidly reversed by the addition of an FKBP12-binding competitor molecule (FK506 or rapamycin), indicating that this cell line might be used to screen FK506 derivatives. Using the screening model, hundreds of synthetic FK506 analogs were analyzed. A promising compound, named N308, was obtained. The results showed that N308 could inhibit AP20187induced gene-modified target cell apoptosis and elicit augmentation of neurite extension from both cultured PC-12 cells and chicken dorsal root ganglia cultures. (Journal of Biomolecular Screening 2006:225-235) 
INTRODUCTION
F K506 IS A MICROBIAL PRODUCT that possesses potent immunosuppressive properties and has proven highly effective clinically in preventing both allograft rejection and graft-versus-host disease. [1] [2] [3] The immunosuppressant action of FK506 is thought to be a result of binding to a receptor protein designated as FK506binding protein 12 (FKBP12). The resulting drug-immunophilin complex (i.e., FK506 and FKBP12) subsequently binds to the Ca 2+ -activated phosphatase calcineurin to inhibit its activity and increase levels of phosphorylated calcineurin substrate proteins, thus blocking early T cell activation events including secretion of interleukin-2 and other T cell-derived lymphokines. [4] [5] [6] [7] The struc-ture of FK506 can be divided into parts. One is known as the binding domain, which is responsible for FKBP12 binding, and the other one is known as the effector domain, which is responsible for calcineurin binding. 8 Recent studies have suggested that FK506 possesses neurotrophic activities, [9] [10] [11] [12] which appears to involve FKBPs as target proteins because the effects of FK506 are reversed by rapamycin, a known antagonist of FK506 at FKBPs. Furthermore, the immunosuppressive and neurite outgrowth activities of FK506 are believed to be independent of each other. The immunosuppressive ability of FK506 is related to its binding to calcineurin, which occurs at the effector domain, and its neuroregenerative activity is thought to be determined only by the binding domain, unrelated to the effector one. Because these 2 domains are separable, it has been proposed that modifications to FK506 that preclude the effector domain could yield a novel panel of FK506 derivatives, which bind to FKBP12 but not to the effector protein calcineurin, with loss of its immunosuppressive activity but retention of the neuroregenerative function. [13] [14] [15] This hypothesis has motivated researchers to design and synthesize a number of FK506 mimics, which are FKBP12 binding positive and calcineurin binding negative, which probably retain the proneuroregenerative activities of the parent compound. 8, [12] [13] [14] [16] [17] [18] [19] [20] [21] In 1997, Steiner and others reported one of these nonimmunosuppressive ligands, designated as GPI-1046, which bound to FKBP12 and elicited neurite outgrowth from sensory neuronal cultures with picomolar potency with maximal effects comparable to nerve growth factor. 15 Gold and others reported another potent FKBP12 inhibitor V-10367, which lacked the structural components of FK506 required for calcineurin inhibition. Experimental results demonstrated that the use of V-10367 could increase neurite outgrowth in SH-SY5Y neuroblastoma cells and speed nerve regeneration in the rat sciatic nerve crush model. It was observed that V-10367 was neuroprotective after 24-h delayed administration in a mouse model of diffuse traumatic brain injury through inhibition of calpain-mediated cytoskeletal damage and maintenance of neuronal plasticity. 12, 13, 22 Furthermore, GPI1485 (NIL-A), which possessed neurotrophic activity, was also introduced as a novel nonimmunosuppressant FKBP12 ligand. Animal model data showed that mice given oral NIL-A after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine lesion demonstrated 61% nigrostriatal projections restoration and fiber density recovery in a dose-dependent manner. In addition, reversed motor deficits were observed in rats with 6-hydroxydopamine lesion by GPI1485 treatment. To date, GPI-1485 is in phase 2 clinical trials, as is GPI-1046 (MGI Pharmaceuticals).
In 2004, a new immunophilin ligand, JNJ460, which could interact with both FKBP12 and FKBP52, was characterized. The results showed that JNJ460 could induce neurite outgrowth from freshly explanted dorsal root ganglia (DRG) in a Schwann celldependent manner. 23 In this study, we present an inducible cell apoptosis model based on FKBP12-Bax recruitment by chemical inducers of dimerization (CID) for preliminary screening of these synthetic FK506 derivatives. First, a chimeric molecule FKBP12 (F36V)-mBax was constructed: the gene encoding the full-length murine Bax was fused to 1 FKBP12 (F36V) molecule. In the FKBP12 (F36V) protein, site 36 was mutated from Phe to a smaller hydrophobic amino acid Val to create a hole, which was accommodated by a sterically encumbering "bump" introduced into CID such as AP20187, 24 AP1903, 25 and the like. This modification resulted in the binding of CID to the mutant FKBP12 (F36V) with low or subnanomolar concentration (K d ≈ 0.1 nM-1 nM) rather than ubiquitous wild-type protein. Second, transgenic HEK293 cell lines that expressed this chimeric fusion protein were generated by stable transfection under G418 selection. One of them, a stable cell line named clone 42, was used for the following experiments. We demonstrated that clone 42 was useful for preliminary screening of FK506 derivatives, which were designed and synthesized by Professor Li and his colleagues, with maintenance of the binding domain and deprivation of the effector domain of the parent compound. Our results revealed that 1) the cell line derived from clone 42 expressing the chimeric protein FKBP12 (F36V)-Bax under-went apoptosis in response to AP20187 in a dose-dependent manner, which was further determined by DNA ladder examination and Giemsa staining; 2) by the addition of a monomeric competitor, FK506 or rapamycin, this AP20187-mediated cell death process was partly or almost completely blocked because the drug interfered with the interaction between AP20187 and FKBP12; and 3) using the stable cell line (clone 42), hundreds of candidates of new FKBP12 inhibitors were investigated as well as GPI1046. A potential mimic of the FKBP12 binding domain portion of FK506, designated as N308, was selected. Experimental data showed that N308 could competitively inhibit the induction of apoptosis of the engineered cells treated by AP20187, whereas GPI1046 exhibited little inhibitory activity. Furthermore, examination of neuron growth from both cultured PC12 cells and chicken dorsal root ganglia explants demonstrated that N308 elicited better neurotrophic effect than GPI1046 did. Taking all the data together, we believe that the established AP20187/FKBP12 (F36V)-mBax model is a successful one and can serve as a useful platform for preliminary screening of synthetic FK506 mimics for further discovery and development of a novel type of neuroimmunophilin ligands.
MATERIALS AND METHODS

Antibodies, cell lines, and reagents
HEK293 (ATCC, CRL-1573), a human embryonic kidney cell line, was cultured in Dulbecco's modified Eagle's medium (DMEM)/F12 (1:1) medium containing 10% fetal bovine serum. Cells of the rat pheochromocytoma tumor cell line PC12 (ATCC, CRL-1721) were maintained at 37°C and 5% CO 2 in DMEM supplemented with 10% heat-inactivated horse serum and 5% heatinactivated fetal bovine serum. NIH3T3 (ATCC, CRL-1685), a mouse fibroblast cell line, was cultured in DMEM medium containing 10% fetal bovine serum.
The antibody to murine Bax (cat. 13686E) used was purchased from Pharmingen (San Diego, CA). The murine ascites cells reactive with FKBP12 immunized by FKBP12 purified proteins were produced and provided by Dr. Cui-Ling Shu. Both the chemical reagent AP20187 and vector pC4FV1E were provided by Professor Song Li. All the small molecular compounds tested including N308, GPI1046, FK506, and rapamycin were provided by Professor Song Li and his laboratory.
Construction of FKBP12 (F36V)-mBax chimera expression vector
The gene encoding the full-length murine Bax (579 bp) was obtained from NIH3T3 cell line by reverse transcriptase-PCR methods. An XbaI site and a SpeI site were introduced to the 5′ end and 3′ end, respectively. After double digestion by XbaI and SpeI, followed by dephosphorylation using CIP, the sticky-end mBax gene was subcloned into the SpeI site of the plasmid pC4FV1E, thus resulting in the recombinant expression vector pC4FV1E/mBax. The formed FKBP12 (F36V)-mBax chimera was further identified using restriction enzyme mapping and DNA sequence analysis.
Stable transfection
To generate stable transfectants, HEK293 cells were cotransfected with 2 µg of recombinant expression plasmid pC4FV1E/mBax or pC4FV1E and 0.2 µg of pCDNA3.1(+) (10:1) by using lipofectinAMINE™ (Invitrogen, Carlsbad, CA) in accordance with the instructions provided by the manufacturer. In brief, cells were plated at a density of 3 × 10 5 cells per well in a 6-well plate and grown to 80% confluence. LipofectinAMINE™ (5 µL) was diluted in advance in 100 µL Opti-MEMI, which was allowed to stand for 5 min at room temperature, and the plasmid DNA mixture was dissolved in 100 µL Opti-MEMI serum-free medium. The 2 diluents were then combined and incubated at room temperature for 15 to 45 min. Then, 0.8 mL of Opti-MEMI medium was added into the combination. Cells were washed by Opti-MEMI medium twice, and the lipofectin/plasmid mixture was added. After incubation for 8 h, the medium was replaced by fresh medium. Selection of stably integrated cells was initiated after 2 days by replacing in complete medium supplemented with the geneticin-G418 (400 µg/mL). After about 14 to 20 days, the resistant colonies were observed and then detached by trypsin and transferred into 24-well plates for further expansive growth.
Western blotting
HEK293 cells that stably cotransfected with pC4FV1E/mBax or pC4FV1E and pCDNA3.1 (+) were harvested and washed twice with ice-cold phosphate-buffered saline (PBS). The cell pellets were lysed in ice-cold lysis buffer. After 30 min at 4°C, cleared lysates were centrifuged at 12,000 rpm for 15 min. The supernatant was separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to nitrocellulose membranes. Membranes were blocked with 5% nonfat dry milk for 2 h and incubated overnight at 4°C with anti-mBax antibody or with anti-FKBP12 ascites for detection of FKBP12-mBax fusion protein. The blots were developed using horseradish peroxidaseconjugated secondary antibody and enhanced chemiluminescence (Cell Signaling Technologies, Beverly, MA).
Assay for inducible mBax activation in cell lines by dimerizer (CID) treatment
Cells were plated at 2 to 4 × 10 4 cells/well in 96-well plates. The next day, medium was removed and fresh medium containing a gradient concentration of the chemical compound AP20187 was placed on triplicate wells. AP20187 had been prepared as a 1 mM stock in methanol and was diluted serially in culture medium to the indicated concentrations just before use. The methanol concentration was at or below 0.1%, which alone has no effect on the cells (data not shown). Cell viability on overnight incubation with AP20187 was measured by MTT assays. Viability was counted as a percentage of the cell viability from 0.1% methanol treated control without AP20187 treatment.
Assessment of apoptosis
Cell morphological changes were examined by Giemsa staining. The DNA ladder assay was used for qualitative apoptotic DNA breaks detection by 2% agarose gel electrophoresis. Quantification of apoptotic changes was determined by 2-color analysis of Annexin-V-FITC binding and propidium iodide uptake using flow cytometry according to the guidelines of the manufacturer.
Fluorescence-activated cell sorting (FACS) analyses for FK506 or rapamycin-mediated competitive assays
Cells were plated at 1 to 2 × 10 6 cells in 60-mm tissue culture plates. The next day, medium was removed and fresh medium containing different concentrations of FK506 or rapamycin in the presence of 10 nM AP20187 was placed. Both FK506 and rapamycin were dissolved in DMSO as 5 mg/mL stocks, which were then diluted serially in culture medium to the indicated concentrations just before use. The concentration of DMSO was at or below 0.1%, which alone has no effect on the cells (data not shown). After incubation for 4 to 6 h, the cells were harvested and analyzed on a FACS apparatus by using the Annexin V-FITC apoptosis detection kit (cat. 6693KK; Pharmingen).
Trypan blue exclusive staining
Cells were plated onto 96-well plates at a density of 2 to 4 × 10 4 cells/well. The medium was replaced after 24 h by fresh medium with serially diluted target compounds including N308 and GPI1046, at a final concentration of 0 µM, 1 µM, 10 µM, and 100 µM in the presence or absence of 10 nM AP20187. All the compounds tested were prepared at 10 -1 M stocks in DMSO, which were then diluted serially in culture medium to the indicated concentrations just before use. The concentration of DMSO was at or below 0.1%. Subsequently incubated for 12 to 16 h, the cells were harvested and washed twice in ice-cold PBS. Then the cell pellets were diluted to 5 mL with the medium, and 10 µL was mixed with 10 µL of 0.4% trypan blue. The number of dead cells was counted using a haemocytometer at 20× magnification. Readings were obtained in triplicate. Results were expressed as the percentage of dead cells (ratio of stained cells to the total number of cells). Only N308 had an effect. The percentage of inhibition, normalized with respect to the value of the percentage cell death obtained for the negative control (0 nM AP20187 + 0 µM N308), was calculated by taking the percentage of the dead cells treated by 10 nM AP20187 alone as 100%. Thus, percentage inhibition = (1 -percentage of cells treated by N308 and AP20187/percentage of cells treated by AP20187 alone) × 100.
Cell Model Based on FKBP12 Dimerization
PC12 differentiation assay
Cells were plated at 1 × 10 4 cells/well in 24-well culture plates, which were precoated with rat tail collagen and allowed to attach before the medium was replaced with DMEM medium supple-mented with 2% horse serum, 1% fetal bovine serum, and 2 ng/mL nerve growth factor (NGF) and/or FK506 or rapamycin or GPI1046 or N308. After a 72-h cultivation, the differentiation of PC12 cells was observed under an inverted light microscope and photographed by a Nikon camera. Neurites were identified and Values shown are the means of triplicate wells and are representative of 3 independent experiments. In brief, cells were plated onto 96-well culture plates at a density of 2 to 4 × 10 4 cells/well. After 16 to 24 h, medium was removed and replaced by fresh medium with AP20187 added to the indicated concentration (at final concentrations of 5 nM, 10 nM, 50 nM, and 100 nM). The next day, 10 µL MTT was added and incubated for 4 to 6 h until a purple precipitate was visible. The reaction was stopped with the addition of 100 µL detergent reagent (10% SDS + 0.1 N HCl) and left at 37°C overnight. The optical density was determined at 570 nm on a multiwell plate reader. All samples were assayed in triplicate, and the mean for each experiment was calculated. Cell viability was counted as a percentage of the 0.1% methanol-treated control. The results showed that AP20187 elicited a concentration-dependent reduction in viability of the engineered cells. 
Chicken DRG cultures and neurite outgrowth
Embryos at day 8 to 10 were removed from fertilized chicken eggs, and the DRG were dissected. Whole ganglion explants were cultured in rat tail collagen-coated 35-mm dishes and allowed to attach for 2 h in a cell incubator at 37°C and 5% CO 2 . DMEM medium without serum was then added, containing 0.15 ng/mL NGF and various concentrations of N308 (at final concentrations of 0.1 pM, 1 pM, and 10 pM) or those of GPI1046. The control group was treated only with the same amount of NGF. After 24 to 48 h, the neurite outgrowth around the DRG was observed under an inverted light microscope. We assessed the neurite outgrowth based on the axon length and density.
RESULTS
AP20187-mediated dimerization of murine Bax resulted in a dose-dependent cell apoptosis of the engineered HEK293 cells
Bax is a proapoptotic molecule that belongs to the Bcl-2 protein family. In the native state, Bax is expressed as a monomer in the cytosol. Once activated by death signal stimulation, Bax undergoes dimerization or oligomerization due to conformation changes. The dimeric Bax subsequently translocates to the mitochondria, altering the transmembrane potential and reactive oxygen species production and results in the dysfunction of mitochondria contributing to the target cell death. [26] [27] [28] Previous studies 29 have showed that forced Bax dimerization through the FKBP12-FK1012 system can induce transfected cell apoptosis, in which the semisynthetic bivalent ligand-FK1012 30 100 (b, d) . This is 1 set of representative results from 3 independent experiments. (B) DNA ladder assay. Cells exposed to 50 nM AP20187 for 4 to 6 h were harvested and then washed by ice-cold phosphate-buffered saline twice. Thereafter, the cells were lysed in lysis buffer (10 mM Tris-HCl pH 8.0, 150 mM NaCl, 10 mM EDTA, 0.4% SDS, proteinase K 100 µg/mL) at 50°C for 4 h or 37°C overnight. The lysates were extracted with phenol-chloroform-isoamyl alcohol 3 times, followed by precipitation with ethanol and 0.3 M sodium acetate. After centrifugation at 12,000 rpm for 20 min, the pellets were dissolved in 50 to 100 µL TE buffer. Before 2% agarose gel (prestained by ethidium bromide) electrophoresis, the dissolvent was incubated with RNase A (50 µg/mL; Sigma) at 37°C for 30 min. The DNA fragmentation was visualized under an ultraviolet transilluminator (UVP imagestore 7500). 1 = mock-transfected control with 50 nM AP20187 treatment for 4 to 6 h; 2 = FKBP12 (F36V)-mBax chimera stably transfected HEK293 cells without AP20187 treatment; 3 = FKBP12 (F36V)-mBax chimera stably transfected HEK293 cells (clone 42) with 50 nM AP20187 treatment for 4 to 6 h. The image is representative of 3 independent experiments. mimics the effect of a death signal. In our studies, the fusion protein contains 1 mutated FKBP12 (F36V), fused to full-length murine Bax. HEK293 cells were engineered to stably express the fusion protein. AP20187, a dimeric FK506 derivative, elicited potent and dose-dependent apoptotic death of these engineered cells, with half-maximal activity at roughly 50 nM (Fig. 1A) . Most likely, such AP20187-mediated apoptosis proceeded through the dimer-mediated clustering of the full-length Bax proteins containing the death domain and subsequent activation of the Bax-induced mitochondria-related apoptosis signal transduction pathways.
Cell Model Based on FKBP12 Dimerization
The cell morphological changes were further determined by Giemsa staining. As shown in Figure 2A , engineered HEK293 cells with 50 nM AP20187 treatment exhibited typical morphological changes of the cells undergoing apoptosis such as apoptotic debris and fragmented nucleus. Agarose gel electrophoresis of DNA from FKBP12 (F36V)-mBax chimera modified HEK293 cells treated with AP20187 showed that DNA underwent progressive degradation, yielding a characteristic pattern of DNA ladder fragmentation, which is typical of apoptosis. Untreated cells did not show such DNA fragmentations, and no ladder pattern was ob-served ( Fig. 2B) . All these results confirmed that the engineered HEK293 cells underwent apoptosis in response to AP20187.
FK506 or rapamycin could effectively inhibit AP20187-mediated cell apoptosis
If this apoptosis of gene-modified HEK293 cells was really mediated through dimerization of FKBP12-fusion proteins containing the death domain of Bax induced by the interaction of AP20187 and FKBP12, then monomeric FKBP12 ligands should act as competitive inhibitors of this process. To test this hypothesis, we investigated the ability of FK506 and rapamycin, which are natural products that bind to FKBP12, in blocking such AP20187induced target cell apoptosis. As expected, both these 2 immunosuppressant drugs were shown to be able to competitively inhibit the apoptosis of FKBP12 (F36V)-mBax chimera modified HEK293 cells induced by AP20187 (10 nM) in a dose-dependent manner. By addition of 1 µM FK506 or 6 µM rapamycin, the AP20187-mediated target cell apoptosis was completely reduced to background levels in a concentration-dependent manner in less (B: 2, 3, 4) . Six hours later, cells were incubated with Annexin V-FITC in a buffer containing propidium iodide (PI) and analyzed by flow cytometry. Untreated cells were primarily Annexin V-FITC and PI negative, indicating that they were viable and not undergoing apoptosis. After treatment for 6 h (A: 2, 3, 4; B: 2, 3, 4), there were primarily 3 populations of cells: cells that were viable and not undergoing apoptosis (Annexin V-FITC and PI negative), cells that were undergoing early-time apoptosis (Annexin V-FITC positive and PI negative), and cells that were observed to be Annexin V-FITC and PI positive, indicating that they were in end-stage apoptosis or already dead. Annexin V-FITC negative and PI positive area represented the cells that were damaged. The results showed that the AP20187-mediated target cell apoptosis was inhibited by monomers, FK506, or rapamycin in a dose-dependent manner. It was observed that FK506 at 1 µM or rapamycin at 6 µM could completely reduce the AP20187-mediated cell apoptosis to the background level. This competitive inhibition effect identified that undergoing apoptosis in target cells treated by AP20187 was mediated through AP20187 simultaneously binding to 2 FKBP12 molecules, thus resulting in the dimerization of the downstream Bax proteins and activation of the Bax-mediated apoptosis signal transduction. The results shown are representative of 3 independent experiments. than 6 h (Fig. 3) . This antagonism was specific because no effects were seen on addition of cyclosporine A, a molecule with no affinity for FKBPs (data not shown). The reason why FK506 competed more potently than rapamycin (FK506 at 1 µM elicited the same inhibition effect as that of rapamycin at 6 µM) might be as follows: FK506 is the monomeric precursor of the dimerizer-AP20187; that is, AP20187 is totally synthesized based on the structure of FK506 through joining 2 FK506 monomers by a linker. 24 So, FK506 as parent compound is certainly able to block the AP20187-mediated cell signaling more efficiently.
N308, one of the hundreds of synthetic FK506 derivatives, was capable of blocking AP20187-mediated cell apoptosis
The above results suggest that the constructed FKBP12 (F36V)-mBax model could be applied for preliminary screening of FK506 derivatives targeted to FKBP12 by competitive inhibition assays. Previous studies have demonstrated that FK506 and rapamycin have neurotrophic effects by binding to FKBP12. Moreover, it has been shown that the neurotrophic properties of the immunophilin ligands are independent of their immunosuppressive action, and much effort has been directed toward the design of FKBP12-binding molecules, which are neurotrophic but nonimmunosuppressant for clinical use. In our studies, based on the structure of the FK506-FKBP12 complex and that of the FKBP12 surface-binding pocket, thousands of nonpeptidic organic compounds in the ACD database (Molecular Design Limited, San Leandro, CA) were investigated through a computational screening approach for potential ligands of FKBP12. About 100 compounds were selected, synthesized, and then tested through the constructed FKBP12 (F36V)-mBax model. One of the most promising compounds discovered by scientists at MGI Pharmaceuticals (GPI1046) was used as the control. Among the compounds tested, N308 displayed significant inhibitory activity. As shown in Figure 4 , upon addition of N308, the AP20187mediated cell death was nearly reduced to the background level in a dose-dependent manner (EC 50 ≈ 16.2 µM). The inhibition percentage was 20.11% at 1 µM, 35.20% at 10 µM, and 89.94% at 100 µM, respectively. In addition, at these concentrations, even at the highest as 100 µM, N308 was shown to act in a nontoxic fashion because no morphologic evidence of toxicity was observed in the cells exposed to N308. In contrast, GPI1046 of equimolar concentrations showed no effects, indicating that the affinity of N308 to FKBP12 was higher than that of GPI1046. Structure-based studies of N308 reveal that it possesses at least 25-fold higher binding affinity than GPI1046 when binding to FKBP12. 31 In conclusion, N308 is a new potent inhibitor of FKBP12, which has higher binding affinity to FKBP12 than GPI1046.
N308 increased neurite outgrowth from cultured PC12 cells and chicken DRG explants
The above results indicate that N308 could be an alternative immunoneurotrophic drug candidate in place of GPI1046. To test this hypothesis, we examined the effect of N308 in cultured PC12 cells. Because FK506 and other nonimmunosuppressive immunophilin ligands (GPI1046 and V-10367) have been shown to enhance neurite outgrowth by increasing NGF sensitivity, rather than acting directly on the neurons themselves, we performed the following neurite extension assays in the presence of NGF. Our previous experiments demonstrated that NGF alone can potently stimulate neurite outgrowth in cultured PC12 cells with half-maximal stimulation at 2 ng/mL and maximal augmentation at 50 ng/mL, which is consistent with other reports. 32, 33 Therefore, we used NGF at 2 ng/mL in our evaluations. As expected, all the 4 drugs tested-FK506, rapamycin, GPI1046, and N308-were observed to augment neurite extension in PC12 cells in the presence of NGF (2 ng/ mL), at equimolar concentrations of 10 nM (Fig. 5A) . As shown in Figure 5B , rapamycin exhibited the highest potency, whereas N308 ≥ FK506 = GPI1046. Furthermore, we examined the effects of different concentrations of N308 (at final concentrations of 0.1 nM, 1 nM, 10 nM, 100 nM, and 1000 nM) on neurite augmentation of cultured PC12 cells. The results shown in Figure 5C demonstrate that N308 as little as 0.1 nM produced detectable augmentation with 2 ng/mL NGF. Progressively, greater outgrowth occurred at 1 nM, whereas maximal outgrowth required 10 nM N308 in the presence of NGF (2 ng/mL). To further evaluate the neurotrophic activity of N308, we examined its actions on primary cultures of FIG. 4. Dose-responsive inhibition of AP20187-mediated cell apoptosis by N308. HEK293 cells (clone 42), which contain the fusion protein-FKBP12 (F36V)-mBax, were incubated with 10 nM AP20187 in the presence or absence of the indicated concentrations of N308 (a wholly synthetic FK506 derivative that is devoid of immunosuppression-related domain and retaining FKBP12-binding domain). Sixteen hours later, cell viability was measured by trypan blue exclusion method. Results were expressed as the percentage of dead cells (ratio of stained cells to the total number of cells). Mean values ± SD (n = 3) are plotted. The results showed that the AP20187-mediated cell death was nearly reduced to the background level in a dose-dependent manner upon addition of N308. The concentration of N308 required for 50% inhibition (EC 50 ) was about 16.2 µM.
FIG. 5.
N308 elicited neurite outgrowth in cultured PC12 cells in a nerve growth factor (NGF)-dependent manner. (A) Cell morphological changes of PC12 cells induced by NGF (2 ng/mL) alone or NGF (2 ng/mL) plus rapamycin, FK506, GPI1046, or N308 at 10 nM, respectively. I = NGF (-); II = NGF (+); III = rapamycin + NGF; IV = FK506 + NGF; V = GPI1046 + NGF; VI = N308 + NGF. (B) The number of neurite-bearing cells and their processes were counted from 400 cells for each group. (C) Concentration-response relationship for N308 potentiation of neurite outgrowth in PC12 cells. Cells were treated for 72 h with NGF (2 ng/mL) and various concentrations of N308 (final concentrations of 0, 0.1, 1, 10, 100, and 1000 nM). Neurites were identified and counted from 400 cells for each group. It was observed that N308 at as low a dose as 0.1 nM produced detectable augmentation with 2 ng/mL NGF. Progressively greater outgrowth occurred at 1 nM, whereas maximal outgrowth required 10 nM N308 in the presence of NGF (2 ng/mL). All the results shown are representative of 3 independent experiments. DRG from fertilized chicken eggs at embryonic day 8 to 10. N308 was added at gradient concentrations to the freshly explanted chicken DRG, also in the presence of NGF (0.15 ng/mL) because drugs alone elicited nonneurite outgrowth activity (data not shown). Interestingly, N308 was shown to be potent in augmenting the neurite outgrowth in chicken DRG compared to NGF-alone treatment control, with significant enhancement evidence at as little as 1 pM concentration. And at 100 pM, N308 triggered dramatic neurite extension. As shown in Figure 6 , 100 pM N308 elicited significant neurite outgrowth in the chicken DRG cultures, which was comparable to that observed with equimolar concentra-tions of FK506 and GPI1046 based on the assessment of the number and length of processes around chicken DRG.
DISCUSSION
Previous studies have demonstrated that both FK506 and rapamycin induce dramatic neuroregenerative effects when bound to FKBP12 in experimental models. As known, the structure of FK506 includes 2 domains, a binding domain responsible for binding to FKBP12 and an effector domain responsible for binding to calcineurin. The immunosuppressive activity of FK506 is mediated by the interaction of the FK506-FKBP12 complex with calcineurin, whereas the neuronal activity of FK506 is thought to depend on its FKBP12-binding activity and reside apart from its calcineurin-binding one. This observation is based on the fact that cyclosporine also binds to calcineurin but not to FKBPs and is inactive in promoting neural regeneration. Thus, compounds capable of binding to FKBP12 but lacking an effector domain would be expected to function as nonimmunosuppressive and neurotrophic FKBP12 ligands. Using a computer-aided screening method, a number of small molecular inhibitors of FKBP12 were selected and synthesized by Professor Li and his colleagues as such FK506 derivatives, which are FKBP12 binding positive and calcineurin binding negative, which might be devoid of immunosuppressive activity but possess potent neurotrophic activity of the parent compound.
In the present report, we developed an inducible cell-based model with an apoptotic end point based on FKBP12-mBax dimerization by AP20187 treatment. This cell model was used to screen those FK506 derivatives for potential neurotrophic agents. As a control, GPI1046, currently under phase 2 clinical trials for the treatment of Parkinson disease and neurogenic erectile dysfunction, was included during the cell-mediated drug screening. A small molecule, named N308, was discovered to exhibit higher affinity to FKBP12 than GPI1046, in that it was observed to competitively reduce the AP20187-mediated target cell death to the background level in a concentration-dependent manner, whereas GPI1046 at the same conditions exhibited little effect. Moreover, functional assays demonstrated that N308 elicited significant and substantial neurotrophic activity in both cultured PC12 cells and freshly explanted chicken DRG in an NGF-dependent fashion. Furthermore, in vivo studies identified N308 as a potential neuroprotective agent for treatment of peripheral sympathetic nerve injury induced by 6-hydroxydopamine in mouse models. By comparison to other known neurogenerative promoters such as BDNF, GDNF, or NGF, N308 displays excellent bioavailability, readily crosses the blood-brain barrier, and is active following oral administration (Jun-hai Xiao, Li-li Wang, Song Li, unpublished data). For these reasons, N308 is considered to be a novel neurotropic inhibitor of FKBP12 and may be an alternative drug candidate in place of GPI1046.
Moreover, being a nonpeptide organic compound, N308 is stable and amenable for chemical synthesis and modification. So it may be reasonable to anticipate that further rational modifications of this 1st-generation lead compound by using medicinal chemistry techniques and molecular modeling can yield analogs with higher affinity and better therapeutic properties.
In conclusion, the established cell model reported here provides us with an efficient method to screen a large number of synthetic FK506 mimics to identify several lead candidates for actual biological testing and further animal model evaluation, thus saving much time and money, and in the future, this cell-based model can also serve as a platform to screen for new inhibitors of the peptidyl prolyl cis-trans isomerase (PPIase) activity of FKBP12.
